Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience

Abstract

In this single center retrospective review, there was a significant difference in survival rates between induction strategies. This outcome may be attributable to differences in recipient characteristics between the groups. However, the Alemtuzumab group experienced less episodes of acute cellular rejection within the first year.